PA5-26290

antibody from Invitrogen Antibodies

Targeting: GFPT2 GFAT2

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-26290

Provider

Invitrogen Antibodies

Product name

GFPT2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This antibody is predicted to react with bovine, mouse and rat based on sequence homology.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

400 µL

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer.

Ding X, Liu H, Yuan Y, Zhong Q, Zhong X
Frontiers in oncology 2022;12:811559

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of A2058 cells using a GFPT2 polyclonal antibody (Product # PA5-26290) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 GFPT2 is highly expressed in colon cancer and correlates with poor pathological features. (A) The typical images of GFPT2 expression levels in colon cancer tissues and corresponding paracancerous tissues by immunohistochemistry (IHC). (B) GFPT2 was shown to be significantly higher in colon cancer tissues compared to paracancerous tissues. (D) Representative images of different GFPT2 (negative-, positive+, positive++, positive ++++) protein levels by IHC. (C) Western blot analysis of GFPT2 expression levels in 5 pairs of colon cancer tissues and paracancerous tissues; GAPDH was used as the loading control. (E) GFPT2 protein levels from different TNM stages (I/II stage or III/IV stage) in 83 colon cancer tissues. (F) The different GFPT2 positive levels (-, +, ++, ++++) in I/II stages were 9.80%, 49.02%, 33.33% and 7.85%, respectively; and 3.12%, 34.38%, 37.50% and 25.00% in III/IV stage, respectively. (G) GFPT2 protein levels from different NODE metastasis status (N0, N1, N2) in 83 colon cancer tissues. (H) The positive levels of different GFPT2 (-, +, ++, ++++) were 9.80%, 49.02%, 33.33% and 7.85% in N0 stage, respectively; and 5.26%, 52.63%, 21.05% and 21.06% in N1 stage, respectively; and 0.00%, 7.69%, 61.54% and 30.77% in N2 stage, respectively. (I) The overall survival (OS) of GFPT2 in the TCGA database was used by Kaplan-Meier in 329 COAD samples from TCGA dataset. *P < 0.05; ***P < 0.001; ****P < 0.0001.